US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations
Journal of Clinical Oncology · 2024-12 · 42 (34) · 4103-4113
DOI: 10.1200/jco.24.00427 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2024-12. Verfasst von Asma Dilawari und 18 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Class I Phosphatidylinositol 3-Kinases, Drug Approval. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural FDA HHS.
Abstract (Originalsprache)
PURPOSE The US Food and Drug Administration (FDA) approved capivasertib in combination with fulvestrant for adult patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative, locally advanced, or metastatic breast cancer (MBC) who have received at least one previous endocrine therapy and whose tumors harbor one or more phosphatidylinositol 3-kinase ( PIK3CA )/AKT Serine/Threonine Kinase 1 ( AKT1 )/phosphatase and tensin homolog ( PTEN ) alterations, as detected by an FDA-approved test. PATIENTS AND METHODS Approval was based on CAPItello-291, a randomized, double-blind, multicenter trial of 708 patients with hormone receptor–positive, HER2-negative advanced or MBC, including 289 patients with PIK3CA/AKT1/PTEN tumor alterations. Patients were randomly assigned 1:1 to receive capivasertib 400 mg twice daily for 4 days per week with fulvestrant versus placebo with fulvestrant. Random assignment was stratified by presence of liver metastases, previous treatment with CDK4/6i, cyclin-dependent kinase four and six (CDK4/6) inhibitors, and geographical region. RESULTS A statistically significant progression-free survival (PFS) benefit was demonstrated in the overall population (hazard ratio [HR], 0.6 [95% CI, 0.51 to 0.71]); this result was driven by 289 patients in the biomarker-positive population (HR, 0.5 [95% CI, 0.37 to 0.68]). An exploratory analysis of investigator-assessed PFS in the 313 (44%) patients in the biomarker-negative population showed uncertain benefit (HR, 0.78 [95% CI, 0.60 to 1.01]). With capivasertib, more patients had Grade ≥3 toxicities. Key concerns included hyperglycemia (18% all-grade, 2.8% Grade ≥3), cutaneous toxicity (58% all-grade, 17% Grade ≥3), and diarrhea (72% all-grade, 9% Grade ≥3). CONCLUSION Capivasertib with fulvestrant was approved for patients whose tumors harbored PIK3CA/AKT1/ PTEN alterations. Benefit-risk assessment in this subgroup was favorable based on a statistically significant and clinically meaningful improvement in PFS in the context of an acceptable safety profile including no evidence of a potential detriment in overall survival. By contrast, the benefit-risk was unfavorable in the biomarker-negative population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
- Center for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration, Silver Spring, MD.
- Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD.
ORCID-Profile: Asma Dilawari, Xin Gao, Justin Collazo, Bronwyn Mixter, Shenghui Tang, Richard Pazdur, Laleh Amiri-Kordestani
Förderung
- Intramural FDA HHS
Zitieren
APA
Dilawari, A., Buturla, J., Osgood, C., Gao, X., Chen, W., Ricks, T. K., Schaefer, T., Avasarala, S., Reyes Turcu, F., Pathak, A., Kalavar, S., Bhatnagar, V., Collazo, J., Rahman, N. A., Mixter, B., Tang, S., Pazdur, R., Kluetz, P., & Amiri-Kordestani, L. (2024). US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations. Journal of Clinical Oncology, 42(34), 4103-4113. https://doi.org/10.1200/jco.24.00427
Vancouver
Dilawari A, Buturla J, Osgood C, Gao X, Chen W, Ricks TK, et al. US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations. Journal of Clinical Oncology. 2024;42(34):4103-4113. doi:10.1200/jco.24.00427
BibTeX
@article{Dilawari2024,
author = {Dilawari, Asma and Buturla, James and Osgood, Christy and Gao, Xin and Chen, Wei and Ricks, Tiffany K and Schaefer, Timothy and Avasarala, Sreedevi and Reyes Turcu, Francisca and Pathak, Anand and Kalavar, Shyam and Bhatnagar, Vishal and Collazo, Justin and Rahman, Nam Atiqur and Mixter, Bronwyn and Tang, Shenghui and Pazdur, Richard and Kluetz, Paul and Amiri-Kordestani, Laleh},
title = {US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {34},
pages = {4103--4113},
doi = {10.1200/jco.24.00427}
}
EUVIMED